There are no studies that have been conducted to actively compare deep TMS and TMS. However, to gain FDA-approval, each therapy underwent similar large-scale clinical trials. The results from the “two trails are not strictly comparable, [but] they provide an idea of the general degree of response seen with each intervention”1.
Response and Remission rates are used to determine how effective a depression treatment is. Response is achieved when a patient has their depressive symptoms improve by at least 50%. Remission is achieved when a patient reaches the point when their symptoms are considered normal mood disturbances or mild. Both Response and Remission are measured using standardized scales. At Prime TMS, we use both Beck’s Depression Inventory (BDI) and the Patient Health Questionnaire (PHQ-9) to measure clients’ improvements during their treatment course.
Because both the BDI and PHQ-9 are recognized as standardized scales, Prime TMS considers both when identifying if clients have achieved Response or Remission. With that in mind, Prime TMS is currently producing a Response rate of 88.2% and a Remission rate of 52.9% from its Lawrence facility (n=17).
Although we have our own results, we encourage potential clients to look at the original studies which granted both TMS and deep TMS FDA-approval. These studies report different numbers than our individual facility, and both were done in a clinical setting that allows them a more direct comparison.
Both the TMS and deep TMS studies reported their subjects’ Remission rates after receiving 4 weeks of treatments. Exactly 32.6% of the deep TMS therapy subjects who were receiving the actual treatments (not the placebo treatment) reached Remission, while only 7.1% to 9% of the subjects receiving TMS therapy reached Remission1. The TMS study did not report their rates of Response, but in the deep TMS study, a Response rate of 38.4% was achieved1. Using these numbers, we know that 71% of the subjects in the original deep TMS study had between 50% and 100% relief from their depressive symptoms.